选择性JAK1抑制剂伊伐莫替尼治疗活动性强直性脊柱炎患者的疗效与安全性:一项适应性无缝2/3期试验结果
这项随机、双盲、适应性2/3期试验评估选择性JAK1抑制剂伊伐莫替尼治疗活动性强直性脊柱炎的疗效与安全性。2期从2、4、8 mg每日一次及安慰剂中选出4 mg为推荐剂量;3期将患者1:1随机分配至伊伐莫替尼4 mg或安慰剂治疗12周,第12周起全部接受伊伐莫替尼4 mg至第24周。第12周伊伐莫替尼4 mg组ASAS20应答率显著高于安慰剂组(48.7% vs 29.0%;单侧P=0.0001),疗效维持至24周,安全性可耐受。
要点
- 第12周ASAS20应答率伊伐莫替尼4 mg组48.7% vs 安慰剂组29.0%(单侧P=0.0001)。
- ASAS40应答率伊伐莫替尼4 mg组32.1% vs 安慰剂组18.3%,其余次要终点亦支持伊伐莫替尼4 mg。
- 安慰剂对照期治疗中出现的不良事件发生率伊伐莫替尼组79.7% vs 安慰剂组65.6%。
核心结论
- 与安慰剂相比,伊伐莫替尼4 mg在第12周显著改善活动性强直性脊柱炎的体征和症状,疗效维持至24周,安全性可耐受。
- 这些发现支持伊伐莫替尼4 mg作为活动性强直性脊柱炎的一种新治疗选择。
研究设计与样本
- 随机、双盲、适应性2/3期试验,评估新型选择性JAK1抑制剂伊伐莫替尼治疗活动性强直性脊柱炎。
- 2期患者按1:1:1:1随机接受伊伐莫替尼2、4或8 mg或安慰剂每日一次治疗12周,基于中期分析选择伊伐莫替尼4 mg为推荐剂量。
- 3期患者按1:1随机接受伊伐莫替尼4 mg或安慰剂治疗12周,第12周起全部患者接受伊伐莫替尼4 mg每日一次至第24周。
- 整个研究共随机504例患者,其中伊伐莫替尼4 mg组187例、安慰剂组186例。
主要发现
- 第12周ASAS20应答率伊伐莫替尼4 mg组48.7% vs 安慰剂组29.0%(单侧P=0.0001),伊伐莫替尼4 mg组显著更高。
- ASAS40应答率伊伐莫替尼4 mg组32.1% vs 安慰剂组18.3%,其余所有次要终点亦支持伊伐莫替尼4 mg。
- 疗效维持至24周。
- 安慰剂对照期治疗中出现的不良事件发生率伊伐莫替尼组79.7% vs 安慰剂组65.6%。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This randomized, double-blind, adaptive phase 2/3 trial aimed to evaluate the efficacy and safety of ivarmacitinib, a novel selective JAK1 inhibitor, in patients with active ankylosing spondylitis (AS). METHODS: In phase 2, patients were randomized (1:1:1:1) to receive ivarmacitinib at a dose of 2, 4, or 8 mg or placebo once daily for 12 weeks. Based on interim analysis, ivarmacitinib 4 mg was selected as the recommended dose. In phase 3, patients were randomized (1:1) to receive ivarmacitinib 4 mg or placebo for 12 weeks; from week 12 onward, all patients received ivarmacitinib 4 mg once daily through week 24. The primary end point was the proportion of patients achieving a ≥20% improvement in the Assessment of SpondyloArthritis international Society (ASAS20) response criteria at week 12. RESULTS: During the entire study, 504 patients were randomized (ivarmacitinib 4 mg, n = 187; placebo, n = 186). At week 12, the ASAS20 response rate was significantly higher in the ivarmacitinib 4 mg group compared to the placebo group (48.7% vs 29.0%; one-sided P = 0.0001). The ASAS40 response rate (32.1% vs 18.3%) and all other secondary end points also favored ivarmacitinib 4 mg. Efficacy was sustained through 24 weeks. During the placebo-controlled period, treatment-emergent adverse events occurred in 79.7% of the ivarmacitinib group and 65.6% of the placebo group. CONCLUSION: Ivarmacitinib 4 mg significantly improved the signs and symptoms of AS at week 12 compared to placebo, with sustained efficacy through 24 weeks and a tolerable safety profile. These findings support ivarmacitinib 4 mg as a new treatment option for active AS.
引用
- Liu X, Xu L, Zhao C, et al. Efficacy and Safety of Ivarmacitinib, a Selective JAK1 Inhibitor, in Patients With Active Ankylosing Spondylitis: Results From an Adaptive Seamless Phase 2/3 Trial. Arthritis Rheumatol. 2025. PMID: 40509748. doi:10.1002/art.43238
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。